EHA 2014 | Breakthrough in relapsed multiple myeloma with PANORAMA 1 study
Paul Richardson
• 13 Jun 2014
At the 19th Congress of the European Hematology Association (EHA) meeting, Prof Paul Richardson, of Dana-Farber Cancer Institute, Boston, MA, discusses the results of PANORAMA 1, which was a global randomized, double-blind, placebo-controlled phase 3 trial of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma. Prof Richardson outlines the primary end-point results and side effects observed, and comments on the clinical meaningfulness of these results. Results of subsets of higher risk groups are also discussed, and Prof Richardson comments on new data with ricolinostat (ACY-1215) in multiple myeloma.
